echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical World News > The 1.5 billion variety is the first to enter the 15 billion contrast agent market after review

    The 1.5 billion variety is the first to enter the 15 billion contrast agent market after review

    • Last Update: 2021-08-05
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Medical Network News, July 29.
    Recently, the product line of Better Pharmaceuticals has continued to have good news: Cefmetazole Sodium for injection was the first to have been reviewed, and the first class new drug BT-101094 capsule was approved for clinical use, and it has reached a cooperation with Guangzhou Kangchen in the field of contrast agents
    .
    With innovation as the driving force for development, the company continues to lay out its research pipeline around the fields of innovative drugs, improved new drugs, and high-end generic drugs
    .
    At present, Better Pharmaceuticals has 39 products that have been evaluated, and 19 products have won the bid collection; 31 new classification applications for the market and 9 injection consistency evaluation applications are under review, and 9 new products are in the sprint for the first imitation; Among the new drugs being researched, BT-1053 tablets and dexmedetomidine hydrochloride nasal spray are in the phase I clinical stage
    .

    The first review of a large variety of 1.
    5 billion! A total of 39 varieties have been
    reviewed
    .
    On July 27, the official website of NMPA showed that Better Pharmaceutical's cefmetazole sodium for injection and cefazolin sodium for injection (1g) passed the consistency evaluation of generic drugs .
    Among them, Better Pharmaceutical's Cefmetazole Sodium for Injection was the first in China to be evaluated, and Cefazolin Sodium for Injection has been evaluated for a specification (0.
    5g) before
    .
    According to data from Meinenet, in 2020, the sales of terminal cefmetazole injections in public medical institutions in China will exceed 1.
    5 billion yuan, and Sichuan Hexin Pharmaceutical's market share will exceed 50%
    .
    Better Pharmaceuticals was the first company to submit a supplementary application for the consistency evaluation of cefmetazole sodium for injection, and it became the first company to pass the evaluation of this product
    .
    Haisco, Asia Pacific Pharmaceutical, Luoxin Pharmaceutical, Hexin Pharmaceutical, Fu'an Pharmaceutical, the supplementary application for consistency evaluation of the species is under review
    .
    In 2020, the sales of terminal cefazolin injections in China's public medical institutions exceeded 3 billion yuan, and Shenzhen China Resources Jiuxin Pharmaceuticals accounted for 66% of the market share
    .
    Cefazolin sodium for injection has been included in the fifth batch of centralized procurement.
    Five companies including China Resources Sanjiu, CSPC, Qilu Pharmaceutical, Jincheng Jinsu, and Better Pharmaceutical were selected
    .
    Up to now, Better Pharmaceuticals (including subsidiaries, the same below) has 39 varieties (59 product specifications) passed/deemed to have passed the consistency evaluation
    .
    Among them, 10 varieties were the first to be reviewed, and 3 varieties, including ketorolac tromethamine injection, ampicillin sodium for injection, and cefodizime sodium for injection, were temporarily reviewed exclusively
    .
    Better Pharmaceuticals passed/deemedly passed the consistency evaluation variety data source: Meinenet MED2.
    0 China Drug Evaluation Database In the five batches and six rounds of centralized procurement carried out by the country, Better Pharmaceuticals has won the bid for its products, with a total of 19 varieties Winning the bid for centralized procurement
    .
    In the fifth batch of centralized procurement that just ended, Better Pharmaceutical won the bid for a total of 11 varieties, becoming one of the big winners of this centralized procurement
    .

      National Pharmaceutical Jicai times selected special cases Source: Shanghai Sunshine Pharmaceutical procurement network
      into 15 billion contrast agent market, grab a large variety of first imitation 1 billion
    recently, Chen Kang Pharmaceutical announced that a subsidiary of Guangzhou Pharmaceutical Kangchen and special times in Cooperation in the field of contrast agents
    .
    In addition to reaching a cooperation with Better Pharmaceuticals, Kangchen Pharmaceuticals also entered into a tripartite cooperation agreement with Better Pharmaceuticals and its wholly-owned subsidiary Ren'an Pharmaceuticals on a certain type of iodine agent project.
    Guangzhou Kangchen and Better Pharmaceuticals Hope to cooperate in the R&D application and market development of APIs and preparations of the contrast agent series products
    .
    With this action, the two sides will further their layout in the field of contrast agents
    .
    Better Pharmaceuticals is a new entrant in the field of contrast agents, covering "raw materials + preparations"
    .
    In February 2021, Better Pharmaceuticals was the first company to submit an application for the registration of iopromide injection in the category 4 imitation; on July 21, the application for imitation of iodixanol injection submitted by Better Pharmaceutical was accepted by the CDE
    .
    At present, the only companies under review for iopromide injection and iodixanol injection market applications are Better Pharmaceuticals, and iopromide injection is expected to be the first imitation
    .
    In 2021, Better Pharmaceuticals reported on the production of contrast media.
    According to data from Mi Nei.
    The terminal contrast agent market for hospitals , county-level public hospitals, urban community centers, and township health centers (Chinese public medical institutions for short) exceeds 15 billion yuan
    .
    Among them, iodixanol injection became the market leader with sales of more than 4 billion yuan, and sales of iopromide injection exceeded 1 billion
    .
    Sales of terminal contrast agents in public medical institutions in China (unit: 100 million yuan) Source: Mynet.
    com.
    The terminal competition pattern of public medical institutions in China.
    Iodixanol injection has been included in the fifth batch of centralized procurement, Yangzijiang Pharmaceutical Group, General Electric, and the company Four companies including Taili and Nanjing Zhengda Tianqing won the bid
    .
    In the domestic market for iopromide injection, only the original manufacturer Bayer is on sale.
    The financial report shows that in 2020, Bayer's iopromide sales will exceed 300 million euros
    .

      10 new class 1 drugs
       are developing , 31 new products are coming.
    Best Pharmaceuticals focuses on researching class 1 new drugs.
    Best Pharmaceuticals insists on independent innovation, and continues to lay out research pipelines around the areas of innovative drugs, improved new drugs, and high-end generic drugs, covering Tumors and autoimmune diseases , anti-infection, respiratory system, cardiovascular and cerebrovascular, mental and nervous system and other fields
    .
    The company has more than 150 research projects, covering 10 class 1 new drugs such as BT-1053 and BT-101, and 3 improved new drugs including remazolam hydrobromide for injection and dexmedetomidine hydrochloride nasal spray.
    , And a high-end generic drug pipeline with rich gradients
    .
    Among the first class of new drugs published by Better Pharmaceuticals, BT-1053 is a second-generation BTK small molecule inhibitor, intended for the treatment of B-cell lymphoma, and is currently in phase I clinical trials
    .
    BT-101094 capsule has recently obtained clinical implied approval, and its indication is advanced malignant solid tumor
    .
    The data source of the consistency evaluation (including new classifications) of Better Pharmaceuticals under review: Mynet.
    com MED2.
    0 Chinese drug review database.
    The data shows that there are currently 31 new registered classifications under review by Better Pharmaceuticals, which have been approved.
    After batch production, it will be deemed to have passed the consistency evaluation
    .
    Among them, there are 9 and 7 anti-infective drugs for respiratory system and systemic use respectively
    .
    No first imitation (including the first imitation of the dosage form) has been approved for 9 varieties, and Better Pharmaceuticals will compete with a number of pharmaceutical companies for the first imitation
    .
    In terms of supplementary applications for consistency evaluation, 10 products of Better Pharmaceutical are under review and approval
    .
    Except for digoxin tablets, all other varieties are injections
    .
    Four varieties of dexamethasone sodium phosphate injection, digoxin tablets, amikacin sulfate injection, and ozagrel sodium for injection were first declared by Better Pharmaceuticals, and it is likely to become the first company to pass the review
    .
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.